Europe Blau Syndrome Market, By Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Europe Blau Syndrome Market Analysis and Size
Several advancements in the health care industry of blau syndrome will impact in launching new product by the several manufacturers into the market, improving its demand along with availability of off-label drugs. Furthermore, everyday changing technologies also puts a hindrance for physicians to perform numerous kinds of genetic tests. Presently, numerous research studies are taking place which is projected to create a competitive advantage for manufacturers to develop advanced and innovative blau syndrome drugs which is projected to provide several other opportunities in the blau syndrome market.
Data Bridge Market Research analyses a growth rate in the blau syndrome market in the forecast period 2023-2030. The expected CAGR of blau syndrome market is tend to be around 12.5% in the mentioned forecast period. The market is valued at USD 1.85 million in 2022, and it will grow upto USD 4.75 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Europe Blau Syndrome Market Scope and Segmentation
2023 to 2030
2021 (Customizable to 2015 - 2020)
Revenue in USD Million, Volumes in Units, Pricing in USD
Therapeutic Areas (Skin Rash, Inflammation), Route of Administration (Oral, Parenteral, Topical, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
Market Players Covered
Abbvie, Inc (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc. (U.S.), Amgen Inc. (U.S.), Janssen Global Services, LLC (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Hikma Pharmaceuticals PLC (U.K.), Fulgent Genetics (U.S.), Invitae Corporation (U.S.), Swedish Orphan Biovitrum AB (Sweden), Alkem Labs Ltd (India), Accord Healthcare (U.K.), Zydus Group (India), Amneal Pharmaceutical Inc. (U.K.), CENTOGENE N.V. (Germany)
Blau Syndrome typically presents in childhood with the triad of granulomatous dermatitis, arthritis, and uveitis. This syndrome is also termed as familial juvenile systemic granulomatosis. Even though a skin rash is not necessarily a ubiquitous feature of Blau syndrome, it is mostly the first sign of disease if it is available. In the majority of the cases, a normal rash appears within the first year of life and presents as discrete, erythematous papules. In this condition, the most common feature, which is arthritis, tends to rise between the ages of 2 to 4 years.
Europe Blau Syndrome Market Dynamics
- Increasing Diagnostic Procedures
There have been increasing diagnostic procedures available which boosts the market growth. Optical coherence tomography (OCT) may be used to depict the extent of ocular disease. Skin or synovial biopsy may be used that will reveal noncaseating granulomas. Out of these two options, skin biopsy is less invasive and has showed higher accuracy. Furthermore, next generation sequencing may be used to test for causative NOD2 mutations, that will confirm the diagnosis. X-rays show dysplastic changes, such as camptodactyly, carpal dysplasia, abnormal ulna and second metacarpal bone shape, abnormal distal radial epiphysis, short ulna. Complete blood count (CBC), C-reactive protein (CRP), serum angiotensin-converting enzyme (ACE), erythrocyte sedimentation rate (ESR), antinuclear antibody (ANA), anti-neutrophilic cytoplasmic antibody (ANCA), anti-dsDNA antibody, Lyme disease serology, rheumatoid factor (RF), RPR/VDRL, human leukocyte antigen (HLA) testing, tuberculin skin test, pathergy skin test are the types of tests that can be performed.
- Growing Treatment Options
Treatment options such as corticosteroids also have utility during quiescent periods. The prolonged need for corticosteroids and the frequency of refractory symptoms signify the use of immunosuppressants such as mycophenolate mofetil, methotrexate, or azathioprine. For this reason, the wide use of monoclonal antibodies to target these cytokines has become helpful; though, variable degrees of efficacy have been witnessed in the literature. It is difficult to determine the true therapeutic benefit of these agents due to contrasting results and the relatively scarce amount of data available. Though medical management is the keystone of treatment for patients with Blau syndrome, operative intervention is also used in certain scenarios. There are many ocular diseases, wherein many inflammatory sequelae should be addressed surgically. Patients may opt to undergo joint fusion procedures because of severe, unrelenting arthritis. Thus, this boosts the market growth.
- Unavailability of skilled professionals
The wide unavailability of qualified professionals who cannot treat the patients with appropriate treatments could restrict the market growth during the forecast period 2023-2030.
- High Cost of Treatment
The increasing expenditure related with medications hinder the market growth. These inhibitors cost high and people in the developing and underdeveloped countries can lead to the under treatment of numerous patients. This hinders the market growth.
This blau syndrome market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the blau syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
- In 2020, Oncodesign got product selection approval for ODS-101 RIPK2 inhibitor, which is an enzyme mainly responsible for producing innate immune response. Furthermore RIPK2 activates the NOD signalling, henceforth proved to be an efficient drug target for the treatment of Blau syndrome. This product selection aided the company in putting its foot in market for the treatment of Blau syndrome.
- In 2019, CENTOGENE collaborated with Pfizer Inc., according to which CENTOGENE will provide genetic information associated with rare disease involving Blau syndrome to Pfizer. This agreement aided the company to increase the growth of its market for rare disease.
Europe Blau Syndrome Market Scope
The blau syndrome market is segmented on the basis of therapeutic areas, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Skin Rash
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Blau Syndrome Market Regional Analysis/Insights
The blau syndrome market is analyzed and market size insights and trends are provided by therapeutic areas, route of administration, end-users and distribution channel as referenced above.
The major countries covered in the blau syndrome market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
Europe is increasing the market due to increasing incidence of autoimmune genetic disorders.
In the Europe region, Germany is also leading the market growth because of growing occurrence of autoimmune inflammatory disorder and increasing demand for all types of treatment for the same.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Blau Syndrome Market Share Analysis
The blau syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to blau syndrome market
Key players operating in the blau syndrome market include:
- Abbvie, Inc (U.S.)
- Novartis AG (Switzerland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Pfizer Inc. (U.S.)
- Amgen Inc. (U.S.)
- Janssen Global Services, LLC (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Hikma Pharmaceuticals PLC (U.K.)
- Fulgent Genetics (U.S.)
- Invitae Corporation (U.S.)
- Swedish Orphan Biovitrum AB (Sweden)
- Alkem Labs Ltd (India)
- Accord Healthcare (U.K.)
- Zydus Group (India)
- Amneal Pharmaceutical Inc. (U.K.)
- CENTOGENE N.V. (Germany)